Release Date: 12-Jul-2024
At present, four bispecific antibodies are undergoing regulatory review, with all four under evaluation by the FDA, and two also being reviewed by the EMA. This diverse pipeline included candidates targeting both hematological and solid cancers, reflecting the broad therapeutic potential of bispecific antibodies across different diseases types. The regulatory review process underscores the rigorous evaluation of safety and efficacy data to ensure patient safety and therapeutic benefit. As these candidates advance through regulatory review, they represent promising additions to the growing arsenal of bispecific antibodies, offering hope for improved treatment outcomes in both hematological and solid malignancies.
Download Report:
https://www.kuickresearch.com/report-bispecific-antibody-market-bispecific-antibodies-market